Sign In
Buy FBRX
$17.00
-1.18 (-6.46%)
At Close: Jun 03, 2026
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules
04:01pm, Monday, 11'th May 2026
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced
Forte Biosciences, Inc. Announces First Quarter 2026 Results and Provides Update
09:01am, Monday, 11'th May 2026
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced
Forte Biosciences: Stunning Bull Run Could Continue Thanks To Near-Term Data Readouts
02:15pm, Friday, 10'th Apr 2026
Forte Biosciences has rebounded from near-liquidation, raising $150m this week and advancing FB102, its multi-indication anti-CD122 antibody, on multiple fronts. FB102 demonstrated statistically signi
Forte Biosciences Announces Pricing of $150 Million Public Offering
09:30pm, Wednesday, 08'th Apr 2026
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (Nasdaq: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the pricing of a publ
Forte Biosciences Announces Proposed Public Offering
04:02pm, Wednesday, 08'th Apr 2026
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (Nasdaq: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced that it has commenced
Forte Biosciences Target of Unusually High Options Trading (NASDAQ:FBRX)
01:09am, Thursday, 02'nd Apr 2026
Forte Biosciences, Inc. (NASDAQ: FBRX - Get Free Report) was the target of some unusual options trading on Wednesday. Investors purchased 30,205 call options on the stock. This represents an increase
Forte Biosciences, Inc. Announces 2025 Results and Provides Update
04:01pm, Tuesday, 31'st Mar 2026
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
04:01pm, Tuesday, 17'th Mar 2026
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on developing FB102, which is a proprietary anti-CD122 monoclon
Forte Biosciences, Inc. Reports Inducement Grants Under NASDAQ Listing Rules
04:01pm, Wednesday, 04'th Mar 2026
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on developing FB102, which is a proprietary anti-CD122 monoclon
Forte Biosciences (FBRX) Upgraded to Buy: Here's What You Should Know
01:01pm, Wednesday, 25'th Feb 2026
Forte Biosciences (FBRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Forte Biosciences, Inc. to Present at Upcoming Investor Meetings
04:01pm, Monday, 09'th Feb 2026
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced
Investors Purchase Large Volume of Forte Biosciences Call Options (NASDAQ:FBRX)
01:42am, Thursday, 05'th Feb 2026
Forte Biosciences, Inc. (NASDAQ: FBRX - Get Free Report) was the recipient of unusually large options trading activity on Wednesday. Stock investors bought 30,205 call options on the company. This is
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules
04:01pm, Monday, 22'nd Dec 2025
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on developing FB102, which is a proprietary anti-CD122 monoclon
Forte Biosciences, Inc. (NASDAQ:FBRX) Given Average Rating of “Moderate Buy” by Brokerages
03:30am, Saturday, 20'th Dec 2025
Forte Biosciences, Inc. (NASDAQ: FBRX - Get Free Report) has earned a consensus rating of "Moderate Buy" from the five research firms that are presently covering the firm, MarketBeat reports. One inve
Federated Hermes Inc. Buys New Shares in Forte Biosciences, Inc. $FBRX
04:21am, Thursday, 11'th Dec 2025
Federated Hermes Inc. purchased a new position in shares of Forte Biosciences, Inc. (NASDAQ: FBRX) in the second quarter, according to its most recent filing with the SEC. The firm purchased 1,072,233
